Intra-Cellular Therapies Company Profile (NASDAQ:ITCI)

About Intra-Cellular Therapies (NASDAQ:ITCI)

Intra-Cellular Therapies logoIntra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company is discovering and developing drugs for the treatment of neurological and psychiatric disorders. Lumateperone (also known as ITI-007) is its lead product candidate. The Company's bipolar depression program consists of two Phase III multi-center, randomized, double-blind, placebo-controlled clinical trials: one to evaluate lumateperone as a monotherapy and the other to evaluate lumateperone as an adjunctive therapy with lithium or valproate. The Company initiated Phase III development of lumateperone for the treatment of agitation in patients with dementia, including Alzheimer's Disease (AD).

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $460.25 million
  • Outstanding Shares: 43,420,000
Average Prices:
  • 50 Day Moving Avg: $12.18
  • 200 Day Moving Avg: $13.90
  • 52 Week Range: $7.85 - $45.20
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.03
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $425,989.00
  • Price / Sales: 1,080.43
  • Book Value: $8.13 per share
  • Price / Book: 1.30
Profitability:
  • EBIDTA: ($117,320,000.00)
  • Return on Equity: -26.85%
  • Return on Assets: -24.31%
Debt:
  • Current Ratio: 3.85%
  • Quick Ratio: 3.85%
Misc:
  • Average Volume: 919,689 shs.
  • Beta: 1.21
  • Short Ratio: 8.8
 

Frequently Asked Questions for Intra-Cellular Therapies (NASDAQ:ITCI)

What is Intra-Cellular Therapies' stock symbol?

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

How were Intra-Cellular Therapies' earnings last quarter?

Intra-Cellular Therapies Inc (NASDAQ:ITCI) released its earnings results on Wednesday, May, 10th. The company reported ($0.62) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.74) by $0.12. The business had revenue of $0.10 million for the quarter, compared to the consensus estimate of $0.02 million. During the same period in the prior year, the business posted ($0.64) EPS. View Intra-Cellular Therapies' Earnings History.

Where is Intra-Cellular Therapies' stock going? Where will Intra-Cellular Therapies' stock price be in 2017?

9 brokerages have issued 1 year price objectives for Intra-Cellular Therapies' stock. Their forecasts range from $10.00 to $75.00. On average, they anticipate Intra-Cellular Therapies' share price to reach $33.14 in the next year. View Analyst Ratings for Intra-Cellular Therapies.

What are analysts saying about Intra-Cellular Therapies stock?

Here are some recent quotes from research analysts about Intra-Cellular Therapies stock:

  • 1. According to Zacks Investment Research, "Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York. " (5/16/2017)
  • 2. Cantor Fitzgerald analysts commented, "March FDA meeting could highlight path forward. Management noted that a meeting with the FDA is planned for late March, at which submission of the NDA will be discussed. We expect the company to have no specific commentary until the meeting minutes have been reviewed. If a plan to file is announced, we believe the market could de-risk the program to a level lower than that after the first Phase 3 trial data were released. Key to FDA approval will clearly be the robustness of the data presented to the Agency. The track record for schizophrenia drug programs is that not all trials are successful. Third Phase 3 bipolar depression trial in the works. Management noted that a third Phase 3 trial in bipolar depression will be conducted to optimize potential success." We believe such a strategy makes sense considering that, like schiophrenia clinical trials, some failure is not unusual. With an extra" clinical trial ongoing, were one to fail, we believe it reasonable that an NDA would still be filable. Enrollment is expected to complete by the end of 2018." (3/2/2017)
  • 3. Cowen and Company analysts commented, "Today ITCI reported 4Q16 results." (3/1/2017)
  • 4. Piper Jaffray Companies analysts commented, "With Intra-Cellular's 4Q16 call set for Weds., 3/1, we're refreshing our thesis and outlining potential outcomes of this business update. Given the 5 months since data, we'll look for visibility on four key issues: 1. Data-driven insight into factors contributing to the 302 trial failure; 2. Preliminary feedback from the FDA on the 302 trial and lumateperone (ITI-007) program; 3. The clinical and regulatory path forward for luma' over the next 12-18 months; 4. Cash required to execute on these plans." (2/23/2017)

Are investors shorting Intra-Cellular Therapies?

Intra-Cellular Therapies saw a decline in short interest in the month of March. As of March 31st, there was short interest totalling 4,612,983 shares, a decline of 9.9% from the March 15th total of 5,119,596 shares. Based on an average daily volume of 626,892 shares, the short-interest ratio is currently 7.4 days.

Who are some of Intra-Cellular Therapies' key competitors?

Who owns Intra-Cellular Therapies stock?

Intra-Cellular Therapies' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), Vanguard Group Inc. (6.32%), BB Biotech AG (4.43%), State Street Corp (2.10%), Clough Capital Partners L P (2.07%) and Morgan Stanley (0.99%). Company insiders that own Intra-Cellular Therapies stock include Alafi Capital Co Llc, Christopher D Alafi, Joel S Marcus, Kimberly E Vanover, Lawrence J Hineline, Lawrence P Wennogle, Michael Halstead and Sharon Mates. View Institutional Ownership Trends for Intra-Cellular Therapies.

Who sold Intra-Cellular Therapies stock? Who is selling Intra-Cellular Therapies stock?

Intra-Cellular Therapies' stock was sold by a variety of institutional investors in the last quarter, including Bogle Investment Management L P DE, Columbus Circle Investors, Weiss Multi Strategy Advisers LLC, State Street Corp, Morgan Stanley, JPMorgan Chase & Co., Credit Suisse AG and Teachers Advisors LLC. Company insiders that have sold Intra-Cellular Therapies stock in the last year include Kimberly E Vanover, Lawrence J Hineline, Michael Halstead and Sharon Mates. View Insider Buying and Selling for Intra-Cellular Therapies.

Who bought Intra-Cellular Therapies stock? Who is buying Intra-Cellular Therapies stock?

Intra-Cellular Therapies' stock was purchased by a variety of institutional investors in the last quarter, including Clough Capital Partners L P, BB Biotech AG, Renaissance Technologies LLC, DekaBank Deutsche Girozentrale, Vanguard Group Inc., First Midwest Bank Trust Division, C WorldWide Group Holding A S and Dimensional Fund Advisors LP. Company insiders that have bought Intra-Cellular Therapies stock in the last two years include Alafi Capital Co Llc and Christopher D Alafi. View Insider Buying and Selling for Intra-Cellular Therapies.

How do I buy Intra-Cellular Therapies stock?

Shares of Intra-Cellular Therapies can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Intra-Cellular Therapies stock cost?

One share of Intra-Cellular Therapies stock can currently be purchased for approximately $10.60.

Analyst Ratings

Consensus Ratings for Intra-Cellular Therapies (NASDAQ:ITCI) (?)
Ratings Breakdown: 5 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.44)
Consensus Price Target: $33.14 (212.67% upside)

Analysts' Ratings History for Intra-Cellular Therapies (NASDAQ:ITCI)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/11/2017Cantor FitzgeraldSet Price TargetBuy$29.00LowView Rating Details
5/2/2017Ladenburg Thalmann Financial ServicesDowngradeBuy -> NeutralHighView Rating Details
5/2/2017Leerink SwannDowngradeOutperform -> Market Perform$29.00 -> $10.00HighView Rating Details
5/1/2017Piper Jaffray CompaniesDowngradeOverweight -> Neutral$22.00 -> $10.00HighView Rating Details
3/1/2017Cowen and CompanyReiterated RatingBuyN/AView Rating Details
12/22/2016BTIG ResearchInitiated CoverageBuy$44.00N/AView Rating Details
9/30/2016Royal Bank of CanadaReiterated RatingOutperform$74.00 -> $49.00N/AView Rating Details
9/29/2016JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
9/29/2016SunTrust Banks, Inc.DowngradeBuy -> Neutral$60.00 -> $15.00N/AView Rating Details
9/29/2015GuggenheimBoost Price TargetBuy$95.00 -> $104.00N/AView Rating Details
(Data available from 5/23/2015 forward)

Earnings

Earnings History for Intra-Cellular Therapies (NASDAQ:ITCI)
Earnings by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)
Earnings History by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017($0.74)($0.62)$0.02 million$0.10 millionViewN/AView Earnings Details
3/1/2017Q4 2016($0.77)($0.64)$0.10 million$0.10 millionViewListenView Earnings Details
11/9/2016Q316($0.84)($0.70)$0.04 million$4.36 millionViewListenView Earnings Details
8/4/2016Q216($0.79)($0.71)$0.02 million$0.23 millionViewN/AView Earnings Details
4/28/2016Q116($0.78)($0.64)$0.02 millionViewListenView Earnings Details
2/25/2016Q415($0.84)($0.67)$0.05 million$30.66 millionViewListenView Earnings Details
11/5/2015Q315($0.66)($0.91)$0.10 millionViewN/AView Earnings Details
8/5/2015Q215($0.72)($0.61)$40.00 million$57.40 millionViewN/AView Earnings Details
4/30/2015Q1($0.68)($0.72)ViewN/AView Earnings Details
3/12/2015Q4 2014($0.49)($0.52)$0.07 millionViewN/AView Earnings Details
11/3/2014Q314($0.34)($0.22)$0.12 millionViewN/AView Earnings Details
8/12/2014Q214($0.24)($0.15)$0.22 millionViewN/AView Earnings Details
5/5/2014Q1 2014($0.23)($0.17)$0.17 millionViewN/AView Earnings Details
3/26/2014($0.41)($0.36)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Intra-Cellular Therapies (NASDAQ:ITCI)
2017 EPS Consensus Estimate: ($2.81)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.70)($0.69)($0.70)
Q2 20172($0.69)($0.65)($0.67)
Q3 20172($0.72)($0.66)($0.69)
Q4 20172($0.78)($0.72)($0.75)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Intra-Cellular Therapies (NASDAQ:ITCI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Intra-Cellular Therapies (NASDAQ:ITCI)
Insider Ownership Percentage: 19.80%
Institutional Ownership Percentage: 64.02%
Insider Trades by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)
Institutional Ownership by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)
Insider Trades by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/5/2017Lawrence J HinelineVPSell1,918$16.58$31,800.44View SEC Filing  
1/5/2017Michael HalsteadSVPSell1,601$16.55$26,496.55View SEC Filing  
1/5/2017Sharon MatesChairmanSell4,081$16.55$67,540.55View SEC Filing  
12/15/2016Kimberly E VanoverSVPSell9,375$15.23$142,781.25View SEC Filing  
12/7/2016Alafi Capital Co LlcMajor ShareholderBuy65,000$16.27$1,057,550.00View SEC Filing  
11/14/2016Christopher D AlafiDirectorBuy34,000$14.50$493,000.00View SEC Filing  
2/29/2016Christopher D AlafiDirectorBuy100,000$29.70$2,970,000.00View SEC Filing  
12/15/2015Lawrence J. HinelineCFOSell45,000$51.45$2,315,250.00View SEC Filing  
12/11/2015Sharon MatesCEOSell51,500$53.87$2,774,305.00View SEC Filing  
12/8/2015Joel S MarcusDirectorSell92,700$54.47$5,049,369.00View SEC Filing  
11/24/2015Lawrence J HinelineCFOSell5,000$55.00$275,000.00View SEC Filing  
6/8/2015Lawrence P WennogleVPSell25,000$26.84$671,000.00View SEC Filing  
3/11/2015Christopher D AlafiDirectorBuy625,000$24.00$15,000,000.00View SEC Filing  
12/9/2014Lawrence J HinelineCFOSell22,500$16.71$375,975.00View SEC Filing  
12/1/2014Moshe AlafiMajor ShareholderBuy1,422$14.75$20,974.50View SEC Filing  
11/28/2014Christopher D AlafiDirectorBuy35,000$14.75$516,250.00View SEC Filing  
11/19/2014Alafi Capital Co LlcMajor ShareholderBuy1,034$14.25$14,734.50View SEC Filing  
11/18/2014Alafi Capital Co LlcMajor ShareholderBuy3,664$14.26$52,248.64View SEC Filing  
11/13/2014Alafi Capital Co LlcMajor ShareholderBuy12,200$15.34$187,148.00View SEC Filing  
11/6/2014Michael HalsteadSVPBuy20,000$15.38$307,600.00View SEC Filing  
10/15/2014Lawrence P WennogleVPSell3,604$15.00$54,060.00View SEC Filing  
10/13/2014Lawrence P WennogleVPSell1,600$15.00$24,000.00View SEC Filing  
10/8/2014Lawrence P WennogleVPSell4,745$15.00$71,175.00View SEC Filing  
10/6/2014Lawrence P WennogleVPSell16,499$15.00$247,485.00View SEC Filing  
9/15/2014Lawrence P WennogleVPSell5,000$15.00$75,000.00View SEC Filing  
9/8/2014Lawrence J HinelineCFOSell300$15.00$4,500.00View SEC Filing  
5/22/2014Lawrence P WennogleVPSell6,000$15.00$90,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Intra-Cellular Therapies (NASDAQ:ITCI)
Latest Headlines for Intra-Cellular Therapies (NASDAQ:ITCI)
Source:
DateHeadline
finance.yahoo.com logoIMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Intra-Cellular Therapies, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - May 23 at 5:33 PM
finance.yahoo.com logoINVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses in Excess of $100,000 from Investment in Intra-Cellular Therapies, Inc. to Contact Brower Piven before the Lead Plaintiff Deadline in Class Action Lawsuit
finance.yahoo.com - May 23 at 5:33 PM
finance.yahoo.com logoIMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Intra-Cellular Therapies, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - May 23 at 11:09 AM
finance.yahoo.com logoITCI INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Intra-Cellular Therapies, Inc. and a Lead Plaintiff Deadline of July 11, 2017
finance.yahoo.com - May 23 at 11:09 AM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Intra-Cellular Therapies, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 11, 2017 - ITCI
finance.yahoo.com - May 22 at 5:28 PM
finance.yahoo.com logoIMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against Intra-Cellular Therapies, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - May 22 at 5:28 PM
businesswire.com logoITCI LOSS NOTICE: Rosen Law Firm Reminds Intra-Cellular Therapies, Inc. Investors of Important Deadline in First ... - Business Wire (press release)
www.businesswire.com - May 19 at 10:45 PM
businesswire.com logoRobbins Arroyo LLP: Intra-Cellular Therapies, Inc. (ITCI) Misled Shareholders According to a Recently Filed Class Action - Business Wire (press release)
www.businesswire.com - May 19 at 10:45 PM
americanbankingnews.com logoIntra-Cellular Therapies Inc (ITCI) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - May 19 at 8:32 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit against Intra-Cellular Therapies, Inc.
finance.yahoo.com - May 19 at 10:33 AM
finance.yahoo.com logoITCI LOSS NOTICE: Rosen Law Firm Reminds Intra-Cellular Therapies, Inc. Investors of Important Deadline in First Filed Class Action
finance.yahoo.com - May 19 at 10:33 AM
finance.yahoo.com logoRobbins Arroyo LLP: Intra-Cellular Therapies, Inc. (ITCI) Misled Shareholders According to a Recently Filed Class Action
finance.yahoo.com - May 19 at 10:33 AM
finance.yahoo.com logoIMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Intra-Cellular Therapies, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - May 19 at 10:33 AM
finance.yahoo.com logoIntra-Cellular Therapies to Present Data on its Novel Compound ITI-333 at the Society of Biological Psychiatry 72nd Annual Meeting
finance.yahoo.com - May 18 at 9:18 AM
finance.yahoo.com logoThe Klein Law Firm Announces a Class Action Filed on Behalf of Intra-Cellular Therapies, Inc. Shareholders and a Lead Plaintiff Deadline of July 11, 2017
finance.yahoo.com - May 18 at 9:18 AM
americanbankingnews.com logoIntra-Cellular Therapies Inc (ITCI) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - May 16 at 11:58 PM
globenewswire.com logoITCI SHAREHOLDER ALERT: The Law Offices of Vincent Wong ... - GlobeNewswire (press release)
globenewswire.com - May 16 at 10:58 PM
businesswire.com logoNewman Ferrara LLP Announces Corporate Governance Investigation of Intra-Cellular Therapies, Inc. - Business Wire (press release)
www.businesswire.com - May 16 at 10:58 PM
finance.yahoo.com logoNewman Ferrara LLP Announces Corporate Governance Investigation of Intra-Cellular Therapies, Inc.
finance.yahoo.com - May 16 at 5:53 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) To Contact Brower Piven Before The Lead Plaintiff Deadline
finance.yahoo.com - May 16 at 10:58 AM
finance.yahoo.com logoIMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Intra-Cellular Therapies, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - May 16 at 10:58 AM
finance.yahoo.com logoITCI SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Intra-Cellular Therapies, Inc. and a Lead Plaintiff Deadline of July 11, 2017
finance.yahoo.com - May 16 at 10:58 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Intra-Cellular Therapies, Inc. (ITCI) and Lead Plaintiff Deadline: July 11, 2017
finance.yahoo.com - May 16 at 10:58 AM
finance.yahoo.com logoIMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Intra-Cellular Therapies, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - May 16 at 10:58 AM
feeds.benzinga.com logoSHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) To Contact Brower Piven Before The Lead Plaintiff Deadli
feeds.benzinga.com - May 15 at 8:49 PM
feeds.benzinga.com logoGainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Intra-Cellular Therapies, Inc. (ITCI)
feeds.benzinga.com - May 15 at 8:49 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Intra-Cellular Therapies, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 11, 2017 – ITCI
finance.yahoo.com - May 15 at 5:30 PM
finance.yahoo.com logoINVESTOR ALERT: Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit against Intra-Cellular Therapies, Inc.
finance.yahoo.com - May 15 at 5:30 PM
finance.yahoo.com logoGlancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Intra-Cellular Therapies, Inc. Investors and Encourages Investors to Contact the Firm
finance.yahoo.com - May 15 at 5:30 PM
finance.yahoo.com logoIMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Intra-Cellular Therapies, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - May 15 at 5:30 PM
feeds.benzinga.com logoLEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Intra-Cellular Therapies, Inc. To Contact The Firm
feeds.benzinga.com - May 15 at 12:11 PM
americanbankingnews.com logoQ2 2017 Earnings Estimate for Intra-Cellular Therapies Inc Issued By SunTrust Banks (ITCI)
www.americanbankingnews.com - May 15 at 7:46 AM
americanbankingnews.com logoCantor Fitzgerald Analysts Give Intra-Cellular Therapies Inc (ITCI) a $29.00 Price Target
www.americanbankingnews.com - May 13 at 6:26 PM
finance.yahoo.com logoEQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Intra-Cellular Therapies, Inc. – ITCI
finance.yahoo.com - May 13 at 1:41 AM
finance.yahoo.com logoIMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Intra-Cellular Therapies, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - May 13 at 1:41 AM
americanbankingnews.com logoBrokers Offer Predictions for Intra-Cellular Therapies Inc's FY2017 Earnings (ITCI)
www.americanbankingnews.com - May 12 at 12:52 PM
finance.yahoo.com logoIMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of Intra-Cellular Therapies, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - May 11 at 11:36 PM
finance.yahoo.com logoEQUITY ALERT: Rosen Law Firm Continues to Investigate Securities Claims Against Intra-Cellular Therapies, Inc. - ITCI
finance.yahoo.com - May 11 at 6:35 PM
americanbankingnews.com logoIntra-Cellular Therapies Inc (ITCI) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 10 at 4:36 PM
finance.yahoo.com logoIntra-Cellular Therapies Reports First Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - May 10 at 1:14 PM
marketbeat.com logoIntra-Cellular reports 1Q loss
marketbeat.com - May 10 at 8:13 AM
americanbankingnews.com logoIntra-Cellular Therapies Inc (ITCI) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - May 10 at 12:50 AM
globenewswire.com logoIntra-Cellular Therapies Presents Data Supporting the Potential for Potent and Rapid Antidepressant Activity with ... - GlobeNewswire (press release)
globenewswire.com - May 8 at 5:38 PM
finance.yahoo.com logoIntra-Cellular Therapies Presents Data Supporting the Potential for Potent and Rapid Antidepressant Activity with Lumateperone
finance.yahoo.com - May 8 at 8:01 AM
finance.yahoo.com logoIntra-Cellular Therapies To Present at the 19th Annual Conference of the International Society for Bipolar Disorders
finance.yahoo.com - May 4 at 11:45 AM
finance.yahoo.com logoIMPORTANT INVESTOR ALERT: Lundin Law PC Announces an Investigation of Intra-Cellular Therapies, Inc. and Advises Investors with Losses to Contact the Firm
finance.yahoo.com - May 3 at 10:33 PM
americanbankingnews.com logoIntra-Cellular Therapies (ITCI) Receiving Somewhat Positive Press Coverage, Analysis Shows
www.americanbankingnews.com - May 3 at 5:24 PM
americanbankingnews.com logoIntra-Cellular Therapies Inc (ITCI) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - May 2 at 5:12 PM
finance.yahoo.com logoINVESTOR ALERT: Goldberg Law PC Announces an Investigation of Intra-Cellular Therapies, Inc.
finance.yahoo.com - May 2 at 4:26 PM
finance.yahoo.com logoInvestor Alert: Kaplan Fox Announces Investigation Of Intra-Cellular Therapies, Inc.
finance.yahoo.com - May 2 at 4:26 PM

Social

Chart

Intra-Cellular Therapies (ITCI) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by MarketBeat.com Staff